Organovo Holdings, Inc. (Rebranded as VivoSim Labs, Inc.) Overview
Pro stress-test →Organovo is a clinical stage biotechnology company developing drugs demonstrated effective in 3D human tissues, using proprietary technology to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. The company pivoted from a tissue products platform to a focused drug discovery engine after successfully monetizing its lead candidate FXR314.
Strategic Profile
Pro stress-test →Organovo maintains valuable 3D human cellular IBD models that have demonstrated utility through successful development and monetization of FXR314, positioning the company to identify additional IBD therapeutic candidates with higher probabilities of clinical success - functioning as a specialized drug discovery engine that can generate partnerable assets with a repeatable business model. The company is transforming into VivoSim Labs, Inc., with the name change effective April 24, 2025, and a new ticker symbol 'VIVS' on the Nasdaq Capital Market.
Competitive Landscape
Pro stress-test →Company aims to disrupt the $10B+ animal testing market with more predictive methods; VivoSim's liver model has demonstrated industry-best correlation rates with known clinical failures and projects 50% reduction in clinical trial failures due to liver toxicity. Competing against traditional animal testing models and emerging in vitro biotech platforms.
Industry Context
Organovo Holdings, Inc. (Rebranded as VivoSim Labs, Inc.) operates in Biotechnology - 3D Tissue Engineering / Bioprinting.
Key facts
Founded: 2007 · Headquarters: San Diego, California